<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04937816</url>
  </required_header>
  <id_info>
    <org_study_id>1245-0171</org_study_id>
    <nct_id>NCT04937816</nct_id>
  </id_info>
  <brief_title>This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations</brief_title>
  <official_title>A Meta-Analysis of Amputation Risk in Empagliflozin Studies (1245.25, 1245.110, 1245.121)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this exploratory meta-analysis is to evaluate the frequencies,&#xD;
      incidence rates, and hazard ratios of lower-limb amputation (LLA) events (primary outcome)&#xD;
      and of adverse events related to amputation (secondary outcome) in patients treated with&#xD;
      empagliflozin compared with placebo in the pooled population of the long-term studies&#xD;
      1245.25, 1245.110, and 1245.121 (SAF-M1), in the pooled population of studies 1245.110 and&#xD;
      1245.121 (SAFM2), and in each of the 3 studies separately.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Actual">July 13, 2021</completion_date>
  <primary_completion_date type="Actual">July 13, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of lower-limb amputation (LLA) events</measure>
    <time_frame>Up to 81 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events related to amputation</measure>
    <time_frame>Up to 81 months.</time_frame>
  </secondary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Actual">14000</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>EMPA-REG - Placebo</arm_group_label>
    <description>Participants of the EMP-REG OUTCOME study (1245.25) who received placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EMPA-REG - Empagliflozin low dose</arm_group_label>
    <description>Participants of the EMPA-REG OUTCOME study (1245.25) who received a low dose of empagliflozin once daily (QD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EMPA-REG - Empagliflozin high dose</arm_group_label>
    <description>Participants of the EMP-REG OUTCOME study (1245.25) who received a high dose of empagliflozin once daily (QD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EMPEROR-Preserved - Empagliflozin</arm_group_label>
    <description>Participants of the EMPEROR-Preserved study (1245.110) who received empagliflozin once daily (QD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EMPEROR-Preserved - Placebo</arm_group_label>
    <description>Participants of the EMPEROR-Preserved study (1245.110) who received placebo once daily (QD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EMPEROR-Reduced - Empagliflozin</arm_group_label>
    <description>Participants of the EMPEROR-Reduced study (1245.121) who received empagliflozin once daily (QD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EMPEROR-Reduced - Placebo</arm_group_label>
    <description>Participants of the EMPEROR-Reduced study (1245.121) who received placebo once daily (QD).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>EMPA-REG - Placebo</arm_group_label>
    <arm_group_label>EMPEROR-Preserved - Placebo</arm_group_label>
    <arm_group_label>EMPEROR-Reduced - Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>Empagliflozin once daily</description>
    <arm_group_label>EMPA-REG - Empagliflozin high dose</arm_group_label>
    <arm_group_label>EMPA-REG - Empagliflozin low dose</arm_group_label>
    <arm_group_label>EMPEROR-Preserved - Empagliflozin</arm_group_label>
    <arm_group_label>EMPEROR-Reduced - Empagliflozin</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with type 2 diabetes mellitus and increased cardiovascular risk (1245.25),&#xD;
        patients with chronic heart failure with preserved ejection fraction (1245.110), and&#xD;
        patients with chronic heart failure with reduced ejection fraction (1245.121), who were&#xD;
        either treated with empagliflozin or placebo.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for 1245.25:&#xD;
&#xD;
          -  Age ≥18 years, diagnosis of type 2 diabetes mellitus (T2DM)&#xD;
&#xD;
          -  Drug-naïve or pretreated with any background therapy&#xD;
&#xD;
          -  Glycated haemoglobin (HbA1c) criteria&#xD;
&#xD;
               -  Patients who were drug-naïve: HbA1c of 7 to 10%&#xD;
&#xD;
               -  Patients with background therapy: HbA1c of 7 to 9%&#xD;
&#xD;
          -  Body mass index (BMI) ≤45 kg/m2&#xD;
&#xD;
          -  With high cardiovascular risk, defined as ≥1 of the following criteria&#xD;
&#xD;
               -  History of myocardial infarction (&gt;2 months prior to enrollment)&#xD;
&#xD;
               -  Multi-vessel coronary artery disease: ≥2 major vessels or left main coronary&#xD;
                  artery&#xD;
&#xD;
               -  Single-vessel coronary artery disease with no scheduled&#xD;
                  revascularization/previously unsuccessful revascularization&#xD;
&#xD;
               -  Hospital discharge due to unstable angina pectoris (&gt;2 months prior to&#xD;
                  enrollment)&#xD;
&#xD;
               -  History of stroke (&gt;2 months prior to enrollment)&#xD;
&#xD;
               -  Peripheral occlusive arterial disease&#xD;
&#xD;
        Inclusion criteria for 1245.110 and 1245.121&#xD;
&#xD;
          -  Age ≥18 years (Japan, age ≥20 years)&#xD;
&#xD;
          -  Chronic heart failure (HF) new york hear association (NYHA) class II to IV&#xD;
&#xD;
          -  Ejection fraction (EF) and N-terminal of the prohormone brain natriuretic peptide&#xD;
             (NT-proBNP) criteria&#xD;
&#xD;
               -  1245.110: preserved EF (Left ventricular ejection fraction (LVEF) &gt;40%) and&#xD;
                  elevated NT-proBNP (&gt;300 pg/ml; &gt;900 pg/ml for patients with atrial fibrillation)&#xD;
&#xD;
               -  1245.121: reduced EF (LVEF ≤40%) and elevated NT-proBNP (≥2500 pg/ml if EF 36 to&#xD;
                  40%, ≥1000 pg/ml if EF 31 to 35%, ≥600 pg/ml if EF ≤30% or if EF ≤40% with&#xD;
                  documented hospitalisation for HF within 12 months prior to screening; for&#xD;
                  patients with atrial fibrillation, double the level of NT-proBNP is applied for&#xD;
                  each EF category)&#xD;
&#xD;
          -  1245.110 only: structural heart disease within 6 months or documented hospitalisation&#xD;
             for HF within 12 months prior to screening&#xD;
&#xD;
          -  1245.121 only: stable dose of medical therapy for HF consistent with local and&#xD;
             international cardiology guidelines&#xD;
&#xD;
        Exclusion criteria for 1245.25&#xD;
&#xD;
          -  Uncontrolled hyperglycemia: fasting plasma glucose &gt;240 mg/dl&#xD;
&#xD;
          -  Severe renal impairment defined as eGFR &lt;30 ml/min by Modification of diet in renal&#xD;
             disease (MDRD) formula&#xD;
&#xD;
          -  Intake of an investigational drug in another trial within 30 days prior to intake of&#xD;
             study medication in this trial, or participating in another trial (involving an&#xD;
             investigational drug and/or follow-up)&#xD;
&#xD;
        Exclusion criteria for 1245.110 and 1245.121&#xD;
&#xD;
          -  Myocardial infarction, coronary artery bypass graft surgery or other major&#xD;
             cardiovascular surgery, stroke or transient ischaemic attack ≤90 days before screening&#xD;
&#xD;
          -  Heart transplant recipient, or listed for heart transplant&#xD;
&#xD;
          -  Acute decompensated HF&#xD;
&#xD;
          -  Systolic blood pressure (SBP) ≥180 mmHg at randomisation&#xD;
&#xD;
          -  Symptomatic hypotension and/or SBP &lt;100 mmHg at screening or randomisation&#xD;
&#xD;
          -  Impaired renal function defined as Estimated glomerular filtration rate (eGFR) Chronic&#xD;
             Kidney Disease Epidemiology Collaboration Equation (based on serum creatinine value)&#xD;
             &lt;20 ml/min/1.73 m2 or requiring dialysis at screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Boehringer Ingelheim</name>
      <address>
        <city>Ingelheim am Rhein</city>
        <zip>55218</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>June 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.&#xD;
Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.&#xD;
The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://www.mystudywindow.com/msw/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

